Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
MARA Rating in the Workflow: How Market Access & BD Teams Use It to Make Better Asset Calls (MARA Rating stands for Market Access Risk Assessment Rating.) Most valuations overweight
Independent MARA® Ratings quantify HTA reimbursement risk for pharma assets. 5-year 97% precision across 10 domains. Request your report today. MARA Rating Insight Since 2020, assets averaging a 2.9 Comparator Selection score sailed
Every payer’s checklist is different. This week: Health-Related Quality of Life—how patient experience shapes coverage. MARA Rating Insight: Since 2020, drugs averaging a 2.8 HRQoL score secured reimbursement far more often than those
An overview of how different payers prioritize safety and tolerability profiles when assessing new therapies. MARA Rating Insight Since 2020, assets averaging a 3.3 Safety score cleared HTA hurdles more often than those
MARA Rating Insight Since 2020, assets averaging a 3.1 Cost-Effectiveness score sailed through HTA evaluations, while those at just 1.96 were far more likely rejected. That 1.14-point gap often determines whether payers call your
Every payer’s checklist is different. MARA Rating Insight Since 2020, assets with an average Clinical Effectiveness score of 3.1 sailed through HTA evaluations, while those averaging just 2.7 were more often rejected. That 0.4-point
Caution Flags Raised: MARA Rating (B++) Spots Access Risks in Merck’s $10B Verona Deal Merck Acquires Verona Pharma for $10B – Our B++ MARA Rating Warns of Access Hurdles Merck
Over the past five years, almost half of drug launches have fallen short of their sales forecasts due to misjudged pricing and reimbursement (P & R) risks, resulting in significant